A phase II study of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in BRAF V600 mutant melanoma patients with brain and leptomeningeal metastases is also currently recruiting (NCT04511013). This evidence concerns the gene BRAF and melanoma.